3 (Category A & B) shows list of areas that have been removed following pre-screening: Policy Area Financial Baseline Bartholin’s Cysts £180K It was noted that Bartholin’s cysts are mentioned in several other CCGs’ policies but absent from (2016/17) NWL policy and therefore had been identified for review. It was noted that other CCGs’ policy thresholds are relatively low and therefore the impact on activity of a NWL policy is likely to be limited. It was further noted that the expenditure on activity across NWL is relatively low, at approximately £180,000 per year. Continued dose escalation of Closed Chelsea & Westminster Hospital Trust’s proposal was discussed and it was agreed that Trust Adalimumab / Infliximab for should be encouraged to submit a business case demonstrating potential efficiencies across NWL. IBD - Crohn’s Disease & This item has been removed from eth forward planner for now but may be added back in case Ulcerative Colitis upon receipt the business case. Abdominoplasty/Apronectomy Completed A review has been completed and this has been resolved. It was noted that NWL are waiting for the conclusion of other policies prior to consultation on any proposed changes to the Abdominoplasty/Apronectomy policy. Chalazia Closed It was noted that NWL policy thresholds align with NICE guidelines and do not warrant review at this time. Circumcision Closed It was noted that there is an even split in the feedback received from Urology consultants, and therefore agreed that no change in the current policy is required.
3 (Category A & B) shows list of areas that have been removed following pre-screening: Policy Area Financial Baseline Bartholin’s Cysts £180K (2016/17) It was noted that Bartholin’s cysts are mentioned in several other CCGs’ policies but absent from NWL policy and therefore had been identified for review. It was noted that other CCGs’ policy thresholds are relatively low and therefore the impact on activity of a NWL policy is likely to be limited. It was further noted that the expenditure on activity across NWL is relatively low, at approximately £180,000 per year. Continued dose escalation of Adalimumab / Infliximab for IBD - Crohn’s Disease & Ulcerative Colitis Closed Chelsea & Westminster Hospital Trust’s proposal was discussed and it was agreed that Trust should be encouraged to submit a business case demonstrating potential efficiencies across NWL. This item has been removed from eth forward planner for now but may be added back in case upon receipt the business case. Abdominoplasty/Apronectomy Completed A review has been completed and this has been resolved. It was noted that NWL are waiting for the conclusion of other policies prior to consultation on any proposed changes to the Abdominoplasty/Apronectomy policy. Chalazia Closed It was noted that NWL policy thresholds align with NICE guidelines and do not warrant review at this time. Circumcision Closed It was noted that there is an even split in the feedback received from Urology consultants, and therefore agreed that no change in the current policy is required.
item_7iii._3_pdg_prioritisation_summary_for_shadow_joint_committee_v2.docx